期刊文献+

多个炎症指标在强直性脊柱炎活动性评价中的价值 被引量:28

Significance of Several Indications of Inflammation in Assessment of Disease Activity in Ankylosing Spondylitis
下载PDF
导出
摘要 目的:探讨强直性脊柱炎多个炎症指标在强直性脊柱炎活动性评价中的价值。方法:根据Bath强直性脊柱炎活动性指标(BASDAI)对78例患者进行分组,比较活动期组与静止期组的实验室检查指标,包括白细胞及中性粒细胞、血小板、红细胞沉降率、C反应蛋白和免疫球蛋白,并与BASDAI进行相关性分析。结果:活动期组血小板、红细胞沉降率、C反应蛋白和IgA异常率高于静止期患者(P<0.05)。活动期患者C反应蛋白和IgA高于静止期患者(P<0.05)。对所有患者的指标进行相关性分析,C反应蛋白和IgA与BASDAI相关,C反应蛋白与IgA相关。其他指标与BASDAI不相关。结论:在强直性脊柱炎活动期,多个炎症指标如血小板、红细胞沉降率、C反应蛋白与IgA均出现改变。C反应蛋白和IgA与疾病活动性相关,可以作为强直性脊柱炎活动性评价指标。 Objective:To detect the levels of several indications of inflammation including platelet (PLT) ,erythrocyte sedimentation rate(ESR), C-reative protein(CRP) and immunoglobulin(Ig) and to determine the value of these indications in assessment of disease activity in ankylosing spondylitis(AS). Methods:Seventy-eight patients with AS(modified New York criteria ) were studied. Disease activity was assessed by the criterion of the Bath ankylosing spondylitis activity index(BASDAI). Three levels were difined: no activity, ambiguous activity and definite activity. The levels of several indications of inflammation including PLT, ESR, CRP and Ig were detected in all patients. The data of activity were analysed, correlations between these indications and BASDAI were caculated. Results:According to BASDAI,25,24and 29 cases were individed to no activity group, ambiguous activity group and definite activity group. The abnormal rate of PLT, ESR, CRP and IgA in definite activity group were higher than those in no activity group(P〈0.05), while the levels of CRP and IgA in definite activity group were higher than those in no activity group(P〈0.05). There were correlations between CRP, IgA and BASDAI(α=0.05) as well as between CRP and IgA(α=0.05). There was no correlation between other indications and BASDAI. Conclusion: The levels of several indications of inflammation including PLT, ESR, CRP and Ig would be abnomal in activity stage of AS,but only CRP and IgA were correlated to disease activity and would be superior in assessing disease activity in AS.
出处 《实用临床医学(江西)》 CAS 2006年第1期18-20,23,共4页 Practical Clinical Medicine
关键词 强直性脊柱炎 血小板计数 红细胞沉降率 C反应蛋白 免疫球蛋白A ankylosing itis platelet count erythrocyte sedimentation rate C-reative protein
  • 相关文献

参考文献6

  • 1Garrett S,Jenkinson T,Kennedy LG,et al.A new approach to defining disease status in ankylosing spondylitis:the Bath Ankylosing Spondylitis Disease Activity Index[J].J Rheumatol,1994,21(12):2 286-2 291.
  • 2Spoorenberg A,van der Heijde D,de Klerk E,et al.Relative value of erythrocyte sedimentation rate and C-reative protein in assessment of disease activity in ankylosing spondylitis[J].J Rheumatol,1999,26(4):980-984.
  • 3Verma S,Li SH,Badiwala MV,et al.Endothelin antagonism and interleukin-6 inhibition attenuate the protherogentic effects of C-reative protein[J].Circulation,2002,105(16):1 890-1 896.
  • 4Subodh V,Chao-Hung W,Shu-Hong L,et al.C-reative protein attenuates nitric oxide production and inhibits angiogenesis[J].Circulation,2002,106(8):913-919.
  • 5Ahmadi K,Wilson C,Tiwana H,Binder A,et al.Antibodies to Klebsiella pheumoniae lipopolysacchride in patients wita ankylosing spondylitis[J].Br J Rheumatol,1998,37(12):1 330-1 333.
  • 6古洁若,张汉伟,赵丽珂,黄烽,颜光美,余得恩.基质金属蛋白酶-3在强直性脊柱炎中的作用和意义探讨[J].中国药物与临床,2004,4(4):270-276. 被引量:14

二级参考文献28

  • 1[1]Beutler BA.The role of tumor necrosis factor in health anddisease.J Rheumatol,1999,57(1):16-21.
  • 2[2]Braun J,Bollow M,Neure L,et al.Use of immunohistologic and insitu hybridization techniques in the examination of sacroiliac jointbiopsy specimens from patients with ankylosing spondylitis.Arthritis Rheum,1995,38(4): 499-505.
  • 3[3]Brandt J,Haibel H,Sieper J,et al.Infliximab treatment of severeankylosing spondylitis:one-year follow-up.Arthritis Rheum,2002,44(12):2936-2945.
  • 4[4]Brandt J,Haibel H,Cornely D,et al.Successful treatment of activeankylosing spondylitis with the anti-tumor necrosis factor-αmonoclonal antibody infliximab.Arthritis Rheu,2000,43(6):1346-1352.
  • 5[5]Braun J,Brandt J,Listin J,et al.Treatment of active ankylosingspondylitis with infliximab: a randomized controlled multicentertrial.Lancet,2002,359(9313): 1187-1193.
  • 6[8]Gu J,Rihl M,Marker-Hermann E,et al.Clues to pathogenesis ofSpondyloarthropathy derived from synovial-fluid-mononuclearcell gene expression profiles.J Rheumatol,2002,29(10):2159-64.
  • 7[9]Seta N,Granfors K,Sahly H,et al.Expression of host defensescavenger receptors in spondyloarthropathy.Arthritis Rheum,2001,44(4): 931-939
  • 8[10]Elsen M,Spellman P,Brown P,et al.Cluster analysis and display ofgenome-wide expression patterns.Proc Natl Acad Sci USA,1998,95:14863-14868.
  • 9[11]Cunnane G,Fitzgerald O,Beeton C,et al.Early joint erosions andserum levels of matrix metalloproteinase 1,matrix metalloproteinase3,and tissue inhibitor of metalloproteinases 1 in rheumatoidarthritis.Arthritis Rheum,2002,44(10):2263-2274.
  • 10[12]Hotary KB,Yana I,Sabeh F,et al.Matrix metalloproteinases (MMPs)regulate fibrin-invasive activity via MT1-MMP-dependent andindependent processes.J Exp Med,2002,195:295-308.

共引文献13

同被引文献261

引证文献28

二级引证文献118

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部